Literature DB >> 14675187

Dimethylfumarate is a potent inducer of apoptosis in human T cells.

Felix Treumer1, Kejian Zhu, Regine Gläser, Ulrich Mrowietz.   

Abstract

Fumaric acid esters (FAE) have been used for the systemic treatment of psoriasis in Germany for almost 50 years. Recently, it has been shown that dimethylfumarate (DMF) as the main ingredient of the marketed FAE mixture is a potent inhibitor of the nuclear transcription factor NF-kappaB. DMF was also shown to induce apoptosis in various cells. Because T cells play a crucial role in psoriasis pathogenesis, we asked whether DMF and its main metabolite methylhydrogenfumarate (MHF) were able to induce apoptosis in these cells. Purified human T cells were treated with DMF and MHF (1-20 microg/mL) and stimulated with interleukin 2, anti-CD3 antibodies or both for 48 h, and apoptosis was subsequently determined by the expression of Apo2.7 as well as by terminal deoxynucleotide transferase nick end labeling. The expression of antiapoptotic protein Bcl-2 was simultaneously determined. The results showed a dose-and-time dependent up-regulation of Apo2.7 expression and DNA fragmentation by DMF preferable in stimulated T cells. MHF and the solvent dimethyl sulfoxide were without effect. DMF, but not MHF, led to a concentration-dependent decrease of Bcl-2 expression in interleukin-2-stimulated T cells. The data provide evidence that the effect of FAE treatment of psoriasis may at least in part be due to induction of apoptosis in activated T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675187     DOI: 10.1111/j.1523-1747.2003.12605.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  82 in total

Review 1.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors:  Ralf A Linker; Aiden Haghikia
Journal:  Ther Adv Chronic Dis       Date:  2016-06-10       Impact factor: 5.091

2.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.

Authors:  S Schilling; S Goelz; R Linker; F Luehder; R Gold
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

Review 4.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

5.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

Review 6.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

7.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

8.  Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation.

Authors:  Henrik Wilms; Jobst Sievers; Uta Rickert; Martin Rostami-Yazdi; Ulrich Mrowietz; Ralph Lucius
Journal:  J Neuroinflammation       Date:  2010-05-19       Impact factor: 8.322

9.  Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

Authors:  Kenneth P Johnson
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

10.  Update of the management of chronic psoriasis: new approaches and emerging treatment options.

Authors:  Philip M Laws; Helen S Young
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.